FDA Approves Immunotherapy Drug

Written By Carra Buttress

The FDA has approved the immunotherapy drug nivolumab (Opdivo) for patients with metastatic colorectal cancer that has one of two specific genetic features, high microsatellite instability (MSI-H) and mismatch repair deficiency (dMMR). These genetic features are hallmarks of most Lynch Syndrome tumors.

Learn more:
https://www.cancer.gov/news-events/cancer-currents-blog/2017/nivolumab-fda-colorectal

BACK
Carra Buttress
Previous

Two New Breast Cancer Genes Emerge From Lynch Syndrome Gene Study
Next

Important Announcement!